Clinical trial and pharmacokinetics of carboplatin 560 mg/m2 in children.
We report a clinical trial with carboplatin (CBDCA) in 15 children with malignant solid tumors recurrent after or resistant to conventional treatment. Based on previous phase I clinical trials, these children were given a dose of CBDCA 560 mg/m2 by intravenous infusion every 4 weeks. The study includes a pharmacokinetic analysis of CBDCA in three patients. This clinical trial shows the feasibility of this CB-DCA schedule, even after high cumulative doses of previous chemotherapy. As expected the main toxicity was hematologic but the risk of renal and ototoxicity is not excluded and these functions have still to be monitored when this relatively high dose of CBDCA chemotherapy is used.
Doz
F
F
Pediatric Oncology Unit, Institut Curie, Paris, France.
Brugières
L
L
Bastian
G
G
Quintana
E
E
Lemerle
J
J
Zucker
J M
JM
D000293:Adolescent; D016190:Carboplatin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D002648:Child; D002675:Child, Preschool; D003404:Creatinine / Q000493:pharmacokinetics; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D007668:Kidney / Q000187:drug effects; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D009364:Neoplasm Recurrence, Local; D009369:Neoplasms / Q000188:drug therapy*; D012074:Remission Induction; D013921:Thrombocytopenia / Q000139:chemically induced
D003404:Creatinine; D016190:Carboplatin